Patents by Inventor Marco Emgenbroich
Marco Emgenbroich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240130978Abstract: Disclosed is a transdermal therapeutic system comprising an active agent impermeable backing layer, at least one adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and optionally a protective layer for removal before use, a method for its preparation and its use as a medicament.Type: ApplicationFiled: February 17, 2022Publication date: April 25, 2024Inventors: Eva-Marie PRINZ, Marco EMGENBROICH, Birgit BRAUN, Peter BOHNENKÄMPER
-
Publication number: 20240016757Abstract: The present invention relates to aransdermal therapeutic system for the transdermal administration of a systemically active agent having a self-adhesive layer structure. The transdermal therapeutic system includes (A) a backing layer, and (B) a dried biphasic layer. The dried biphasic layer has (a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and (b) an inner phase having a composition that includes at least one active agent. The inner phase forms dispersed deposits in the outer phase, with the dried biphasic layer including (c) from 0.1% to 3.5% of an interface mediator other than silicone oil, with the interface mediator having with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C.Type: ApplicationFiled: August 4, 2023Publication date: January 18, 2024Applicant: LTS Lohmann Therapie-Systeme AGInventors: Marco EMGENBROICH, Johannes Josef LEONHARD, Kristina KASSNER, Aurélia LAPPERT
-
Patent number: 11752110Abstract: Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and C) optionally an additional skin contact layer.Type: GrantFiled: May 20, 2015Date of Patent: September 12, 2023Assignee: LTS Lohmann Therapie-Systeme AGInventors: Marco Emgenbroich, Johannes Josef Leonhard, Kristina Kassner, Aurélia Lappert
-
Publication number: 20230248661Abstract: The present invention relates to transdermal therapeutic systems for the transdermal administration of rotigotine containing a therapeutically effective amount of rotigotine base in a self-adhesive layer structure that includes a backing layer and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase formed from a polymer or a polymer mixture along with an inner phase that includes rotigotine base and a polymer mixture including polyvinylpyrrolidone having a K-Value of at least 80 and at least one further hydrophilic polymer selected from the polymer groups: copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The inner phase forms dispersed deposits in the outer phase. The inventive transdermal therapeutic systems optionally include a skin contact layer.Type: ApplicationFiled: March 24, 2023Publication date: August 10, 2023Applicant: LTS Lohmann Therapie-Systeme AGInventors: Marco EMGENBROICH, Elke KLEIN, Heike KLUTH
-
Publication number: 20230241004Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer.Type: ApplicationFiled: January 11, 2023Publication date: August 3, 2023Applicants: LTS LOHMANN Therapie-Systeme AG, DDP Specialty Electronic Materials US 9, LLCInventors: Marco EMGENBROICH, Eva-Marie PRINZ, Elke KLEIN, Heike KLUTH, Xavier THOMAS, Linda Sue NARTKER
-
Patent number: 11633367Abstract: A transdermal therapeutic system containing rotigotine base in a self-adhesive layer structure. The system includes a backing layer, and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase having a composition including 75% to 100% of a polymer or a polymer mixture, and an inner phase that forms dispersed deposits in the outer phase. The inner phase includes rotigotine base and a polymer mixture of at least two hydrophilic polymers. The hydrophilic polymers are selected from the group of polyvinylpyrrolidones having a K-Value of at least 80, polyvinylpyrrolidones having a K-Value of less than 80, copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The polymer mixture in the inner phase is present in an amount sufficient so that it forms a solid solution with the rotigotine base.Type: GrantFiled: May 20, 2015Date of Patent: April 25, 2023Assignee: LTS Lohmann Therapie-Systeme AGInventors: Marco Emgenbroich, Elke Klein, Heike Kluth
-
Patent number: 11576874Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer.Type: GrantFiled: October 11, 2018Date of Patent: February 14, 2023Assignees: LTS LOHMANN Therapie-Systeme AG, DDP Specialty Electronic Materials US 9, LLCInventors: Marco Emgenbroich, Eva-Marie Prinz, Elke Klein, Heike Kluth, Xavier Thomas, Linda Sue Nartker
-
Publication number: 20220296531Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase comprises the additive and an active agent dissolved therein, the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate proportional to the amount of active agent in the biphasic layer.Type: ApplicationFiled: June 8, 2022Publication date: September 22, 2022Applicant: LTS Lohmann Therapie-Systeme AGInventors: Marco Emgenbroich, Johannes Josef Leonhard, Hans-Michael Wolff
-
Patent number: 11426359Abstract: The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.Type: GrantFiled: May 20, 2015Date of Patent: August 30, 2022Assignee: LTS Lohmann Therapie-Systeme AGInventors: Marco Emgenbroich, Johannes Josef Leonhard, Hans-Michael Wolff
-
Publication number: 20220241215Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent- containing layer structure comprising: A) a backing layer; B) an active agent-containing layer comprising at least one silicone-containing polymer; C) a skin contact layer; and wherein the skin contact layer is an adhesive layer comprising a silicone gel adhesive.Type: ApplicationFiled: July 8, 2020Publication date: August 4, 2022Inventors: Marco EMGENBROICH, Peter KLAFFENBACH, Nico REUM, Gabriel WAUER, Patrick MOHR, Anna SCHLÜTER, Hans-Werner WOLF
-
Publication number: 20220241216Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising: A) a backing layer; B) an active agent-containing layer comprising at least one acrylic polymer; C) a skin contact layer; and wherein the skin contact layer is an adhesive layer comprising a silicone gel adhesive.Type: ApplicationFiled: July 8, 2020Publication date: August 4, 2022Inventors: Marco EMGENBROICH, Peter KLAFFENBACH, Nico REUM, Gabriel WAUER, Patrick MOHR, Anna SCHLÜTER, Hans-Werner WOLF
-
Patent number: 11389421Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.Type: GrantFiled: September 4, 2018Date of Patent: July 19, 2022Assignee: LTS LOHMANN THERAPIE-SYSTEME AGInventors: Marco Emgenbroich, Nico Reum, Jessica Verstraelen, Regine Kaufmann
-
Patent number: 11389410Abstract: The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention.Type: GrantFiled: November 21, 2013Date of Patent: July 19, 2022Assignee: LTS Lohmann Therapie-Systeme AGInventors: Willi Cawello, Aurelia Lappert, Kristina Kassner, Hans-Michael Wolff, Walter Müller, Johannes Josef Leonhard, Marco Emgenbroich
-
Publication number: 20220151949Abstract: The present invention relates to a transdermal therapeutic system formed from (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, in which the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer; a kit containing two transdermal therapeutic systems of the present invention; and methods for the preparation of the transdermal therapeutic system of the present invention. The present invention further relates to methods of treatment based upon the application of the inventive transdermal therapeutic systems once or twice weekly via systems adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: LTS Lohmann Therapie-Systeme AGInventors: Willi CAWELLO, Aurelia LAPPERT, Kristina KASSNER, Hans-Michael WOLFF, Walter MÜLLER, Johannes Josef LEONHARD, Marco EMGENBROICH
-
Publication number: 20220096367Abstract: The present invention additionally relates to a dosage form for an active substance, selected from the group of cannabinoids, for dissolving in the oral cavity, comprising a first film layer and a second film layer, arranged over the first film layer, wherein the composition of the first film layer can be identical to that of the second film layer and comprises a water soluble polymer, the first and second film layer being connected to each other via the overlapping edges thereof, forming at least one cavity, and the cavity being filled with an active substance selected from the group of cannabinoids.Type: ApplicationFiled: January 10, 2020Publication date: March 31, 2022Inventors: Marius BAUER, Michael LINN, Marco EMGENBROICH, Christoph SCHMITZ, Markus MÜLLER
-
Publication number: 20220079887Abstract: The present invention relates to a transdermal therapeutic system (1) comprising an active-substance carrier layer (2) having at least one active-substance-containing polymer matrix (3) applied to the active-substance carrier layer (2), said matrix comprising at least one pressure-sensitive adhesive and at least one pharmacologically active substance absorbable through human or animal skin, and an adhesive carrier layer (6) coated as completely as possible with an active-substance-free pressure-sensitive adhesive (7), said adhesive carrier layer being bonded by means of the active-substance-free pressure-sensitive adhesive (7) directly to the flat side of the active-substance carrier layer (2) facing away from the active-substance-containing polymer matrix (3), wherein the adhesive carrier layer (6) projecting circumferentially beyond the edge of the active-substance carrier layer (2), wherein the system is characterized in that between the active-substance-containing polymer matrix (3) and the active-subType: ApplicationFiled: November 25, 2019Publication date: March 17, 2022Inventors: Nico REUM, Marco EMGENBROICH, Sandra WIEDERSBERG
-
Patent number: 11198800Abstract: A method of inverting the phase arrangement of the silicone phase and the acrylic phase in a silicone acrylic hybrid composition, the silicone acrylic hybrid composition comprising: a) a silicone acrylic hybrid pressure sensitive adhesive, and b) a solvent, wherein the phase arrangement of the silicone phase and the acrylic phase in the initial silicone acrylic hybrid composition forming a continuous external phase and a discontinuous internal phase is determined by the solvent, comprising the step of adding an activator to the silicone acrylic hybrid composition, wherein the activator a) is liquid at 20° C. and 1013 mbar, b) has a boiling point which is higher than the boiling point of the solvent and/or has a vapor pressure at 20° C.Type: GrantFiled: July 19, 2017Date of Patent: December 14, 2021Assignees: LTS LOHMANN Therapie-Systeme AG, DOW SILICONES CORPORATIONInventor: Marco Emgenbroich
-
Publication number: 20210052569Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of nicotine comprising a nicotine-containing layer structure, said nicotine-containing layer structure comprising A) a backing layer and B) a nicotine-containing layer, wherein the transdermal therapeutic system comprises a silicone acrylic hybrid polymer.Type: ApplicationFiled: March 11, 2019Publication date: February 25, 2021Inventors: Michael LINN, Christoph SCHMITZ, Rolf BÖHM, Marco EMGENBROICH
-
Publication number: 20210038532Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer comprising a therapeutically effective amount of the active agent, and C) a skin contact layer comprising at least one silicone acrylic hybrid polymer.Type: ApplicationFiled: March 11, 2019Publication date: February 11, 2021Inventors: Marco EMGENBROICH, Gabriel WAUER, Michael LINN, Rolf BÖHM, Christoph SCHMITZ, Regine KAUFMANN, Hans-Wemer WOLF, Nico REUM, Anna SCHLÜTER
-
Publication number: 20210008000Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer, wherein the active agent-containing layer comprises a therapeutically effective amount of the active agent and at least one silicone acrylic hybrid polymer, and C) a skin contact layer.Type: ApplicationFiled: March 11, 2019Publication date: January 14, 2021Inventors: Marco EMGENBROICH, Gabriel WAUER, Michael LINN, Rolf BÖHM, Christoph SCHMITZ, Regine KAUFMANN, Hans-Wemer WOLF, Nico REUM, Anna SCHLÜTER